Search Results

There are 5217 results for: content related to: Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?

  1. Natalizumab for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    John K MacDonald and John WD McDonald

    Published Online : 24 JAN 2007, DOI: 10.1002/14651858.CD006097.pub2

  2. You have free access to this content
    Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases

    CNS Drug Reviews

    Volume 13, Issue 1, March 2007, Pages: 79–95, Olaf Stüve and Jeffrey L. Bennett

    Version of Record online : 24 APR 2007, DOI: 10.1111/j.1527-3458.2007.00003.x

  3. Natalizumab for relapsing remitting multiple sclerosis

    Intervention Review

    The Cochrane Library

    Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj and Ian Galea

    Published Online : 5 OCT 2011, DOI: 10.1002/14651858.CD007621.pub2

  4. Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience

    Inflammatory Bowel Diseases

    Volume 18, Issue 12, December 2012, Pages: 2203–2208, S.V. Kane, S. Horst, W.J. Sandborn, B. Becker, B. Neis, M. Moscandrew, K.A. Hanson, W.J. Tremaine, D.H. Bruining, W.A. Faubion, D.S. Pardi, W.S. Harmsen, A.R. Zinsmeister and E.V. Loftus

    Version of Record online : 14 MAR 2012, DOI: 10.1002/ibd.22943

  5. You have full text access to this OnlineOpen article
    Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 1, January 2015, Pages: 43–55, Jens Ingwersen, Til Menge, Britta Wingerath, Derya Kaya, Jonas Graf, Tim Prozorovski, Andreas Keller, Christina Backes, Markus Beier, Matthias Scheffler, Thomas Dehmel, Bernd C. Kieseier, Hans-Peter Hartung, Patrick Küry and Orhan Aktas

    Version of Record online : 5 DEC 2014, DOI: 10.1002/acn3.152

  6. Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

    Annals of Neurology

    Volume 77, Issue 3, March 2015, Pages: 425–435, Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson, Celia Oreja-Guevara, Daniele Spitaleri, Michael Barnett, Murat Terzi, Roberto Bergamaschi, Pamela McCombe, Jose Sanchez-Menoyo, Magdolna Simo, Tunde Csepany, Gabor Rum, Cavit Boz, Eva Havrdova, Helmut Butzkueven and on behalf of the MSBase Study Group

    Version of Record online : 17 JAN 2015, DOI: 10.1002/ana.24339

  7. Therapeutic interference with leukocyte recirculation in multiple sclerosis

    European Journal of Neurology

    Volume 22, Issue 3, March 2015, Pages: 434–442, F. Sellebjerg and P. S. Sørensen

    Version of Record online : 13 JAN 2015, DOI: 10.1111/ene.12668

  8. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

    Inflammatory Bowel Diseases

    Volume 13, Issue 1, January 2007, Pages: 2–11, Bruce E. Sands, Richard Kozarek, Jack Spainhour, Charles F. Barish, Scott Becker, Lawrence Goldberg, Seymour Katz, Ronald Goldblum, Rena Harrigan, Deborah Hilton and Stephen B. Hanauer

    Version of Record online : 19 DEC 2006, DOI: 10.1002/ibd.20014

  9. What to expect after natalizumab cessation in a real-life setting

    Acta Neurologica Scandinavica

    Volume 130, Issue 2, August 2014, Pages: 97–102, S. Salhofer-Polanyi, A. Baumgartner, J. Kraus, E. Maida, M. Schmied and F. Leutmezer, The Austrian Tysabri Registry Group

    Version of Record online : 10 APR 2014, DOI: 10.1111/ane.12250

  10. Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi-center study in German speaking countries

    European Journal of Neurology

    Volume 17, Issue 1, January 2010, Pages: 31–37, N. Putzki, O. Yaldizli, M. Mäurer, S. Cursiefen, S. Kuckert, C. Klawe, M. Maschke, B. Tettenborn and V. Limmroth

    Version of Record online : 9 JUL 2009, DOI: 10.1111/j.1468-1331.2009.02728.x

  11. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years

    European Journal of Neurology

    Volume 23, Issue 6, June 2016, Pages: 1101–1109, R. Zivadinov, D. Hojnacki, N. Bergsland, C. Kennedy, J. Hagemeier, R. Melia, D. P. Ramasamy, J. Durfee, E. Carl, M. G. Dwyer and B. Weinstock-Guttman

    Version of Record online : 21 MAR 2016, DOI: 10.1111/ene.12992

  12. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 86, Issue 2, April 2009, Pages: 144–156, Nancy G. Wehner, George Shopp, Ingrid Osterburg, Antje Fuchs, Eberhard Buse and Janet Clarke

    Version of Record online : 12 MAR 2009, DOI: 10.1002/bdrb.20193

  13. You have free access to this content
    Clinically significant liver injury in patients treated with natalizumab

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 9, May 2010, Pages: 1028–1035, S. BEZABEH, C. M. FLOWERS, C. KORTEPETER and M. AVIGAN

    Version of Record online : 16 FEB 2010, DOI: 10.1111/j.1365-2036.2010.04262.x

  14. You have free access to this content
    Monoclonal antibodies in treatment of multiple sclerosis

    Clinical & Experimental Immunology

    Volume 175, Issue 3, March 2014, Pages: 373–384, P. S. Rommer, A. Dudesek, O. Stüve and U.K. Zettl

    Version of Record online : 4 FEB 2014, DOI: 10.1111/cei.12197

  15. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

    European Journal of Neurology

    Volume 19, Issue 5, May 2012, Pages: 783–787, G. Borriello, L. Prosperini, C. Mancinelli, C. Giannì, F. Fubelli and C. Pozzilli

    Version of Record online : 7 NOV 2011, DOI: 10.1111/j.1468-1331.2011.03577.x

  16. You have full text access to this OnlineOpen article
    Comparative efficacy of switching to natalizumab in active multiple sclerosis

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 4, April 2015, Pages: 373–387, Timothy Spelman, Tomas Kalincik, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Ludwig Kappos, Larisa Tsvetkova, Shibeshih Belachew, Robert Hyde, Freek Verheul, Francois Grand-Maison, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Alessandra Lugaresi, Jeannette Lechner-Scott, Celia Oreja-Guevara, Raymond Hupperts, Thor Petersen, Michael Barnett, Maria Trojano, Helmut Butzkueven and on behalf of the MSBase Investigators and the TOP investigators

    Version of Record online : 27 FEB 2015, DOI: 10.1002/acn3.180

  17. You have full text access to this OnlineOpen article
    Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy

    European Journal of Neurology

    Volume 21, Issue 3, March 2014, Pages: 377–e20, M. S. Freedman

    Version of Record online : 15 NOV 2013, DOI: 10.1111/ene.12299

  18. Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis

    The Journal of Clinical Pharmacology

    Volume 57, Issue 8, August 2017, Pages: 1017–1030, Kumar Kandadi Muralidharan, Geoffrey Kuesters, Tatiana Plavina, Meena Subramanyam, Daniel D. Mikol, Sreeja Gopal and Ivan Nestorov

    Version of Record online : 11 APR 2017, DOI: 10.1002/jcph.894

  19. You have free access to this content
    Molecular targeted therapy against the blood–brain barrier in multiple sclerosis

    Clinical and Experimental Neuroimmunology

    Volume 5, Issue s1, December 2014, Pages: 28–34, Takashi Kanda

    Version of Record online : 18 DEC 2014, DOI: 10.1111/cen3.12167

  20. You have full text access to this OnlineOpen article
    CD4 cell response to interval therapy with natalizumab

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 5, May 2015, Pages: 570–574, Regina Berkovich, Daniel M. Togasaki, Steven Y. Cen and Lawrence Steinman

    Version of Record online : 6 MAR 2015, DOI: 10.1002/acn3.190